Nimbus Synergies, a venture capital firm investing in companies using technology to improve outcomes, increase efficiencies, and lower costs in healthcare, is pleased to announce the appointment of Wendy Hurlburt… Read More
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceed This news release constitutes a “designated news release” for the purposes… Read More
Semaglutide 2.4 mg reduced total cardiovascular events by 22% in people with established cardiovascular disease (CVD) and overweight or obesity without diabetes.1 Obesity directly leads to cardiovascular morbidity, mortality and… Read More
Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment1 SCORE is a retrospective, observational analysis… Read More
VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement – Zimislecel… Read More
